Ann: Update on Status of Re-Compliance Listing, page-619

First 619 Last

Share
Profile

Follow
Glitterati

10,175 Posts.

2796

17/05/19

11:57

Post #: 38612708
Share

Originally posted by cfp: ↑

hahaha your a crack up Cosmo, no the first $25 million USD offtake wont be coming from Santa its too early for him silly, I know we are going to be huge when we re-list but how did you arrive at $10.00 a share, also is that USD or AUD, I dont want to get too excited, London I think is pretty close, closer than we know, I understand that it is only a 7 or 8 week timeframe to list over there on the main board, and everything we have sent the ASX is enough for the LSE, as is it enough for other exchanges in Australia, my research tells me, the next biggest exchange in Australia is the NSX, and according to there information sheet on there homepage it is a very quick process, but as a couple of others have stated they would prefer if our dual listing was in a European country, that makes sense as the real money is overseas, the ASX caters for mums and dads and retail, Europe and the Americas are for investors with deep pockets, not long to go I feel and it will be big when it happens

Expand

Great analysis CFP as usual. I agree that the LSE listing could well be just around the corner given the average timelines to set this thing up. Memery Crystal got MOD Resources listed (LSE:MOD) on the LSE and it took just over 3 months from go to whoa; it's been just over 3 months now for WFE since JB initiated this - exciting times ahead my friends, don't let the negative nellies spoil your fun

WFE Price at posting: 2.4¢ Sentiment: Buy Disclosure: Held
8 Upvote

1 Great analysis

Reply

Top Stories

AI stocks: What to expect in 2024-25

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability